Maastricht Pathology 2018

11th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland

19 – 22 June 2018

Hosted by
Department of Pathology
GROW – School for Oncology and Developmental Biology
Maastricht University Medical Center+
Maastricht, NL

Venue
Maastricht Exhibition and Conference Center
Forum 100, 6229 GV Maastricht, NL

Companion Meetings
Association of Clinical Electron Microscopists
Renal EQA and Renal Transplant EQA
## Programme Overview

This Programme is published jointly by the British Division of the International Academy of Pathology, the Dutch Pathological Society (NVVP) and the Pathological Society of Great Britain & Ireland. © 2018

### Fees and Registration

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
</tr>
</tbody>
</table>

### Scientific Sessions Information

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
</tr>
</tbody>
</table>

- Continued Professional Development (CPD)

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
</tr>
</tbody>
</table>

### General Arrangements

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
</tr>
</tbody>
</table>

- Future Meetings

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
</tr>
</tbody>
</table>

### Abstract Reviewers

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
</tr>
</tbody>
</table>

### Detailed Programme — Tuesday 19 June

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
</tr>
</tbody>
</table>

### Detailed Programme — Wednesday 20 June

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
</tr>
</tbody>
</table>

### Detailed Programme — Thursday 21 June

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
</tr>
</tbody>
</table>

- Pathological Society Annual General Meeting

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
</tr>
</tbody>
</table>

- Companion Meeting: ACEM

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
</tr>
</tbody>
</table>

### Detailed Programme — Friday 22 June

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
</tr>
</tbody>
</table>

- The TEFAF Oncology Chair Summit

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
</tr>
</tbody>
</table>

### Industry Sponsored Symposia

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>58</td>
</tr>
</tbody>
</table>

### Trade Exhibition and Sponsors

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
</tr>
</tbody>
</table>

### Index to Presenters (Name and Abstract Number)

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>65</td>
</tr>
</tbody>
</table>

Abstracts of talks and posters can be found at our meeting website: [www.path.org.uk](http://www.path.org.uk)

---

**MEMBERS:** Please pass on all details of this Meeting to any non-members who might wish to participate.

---

**New for Maastricht 2018**

- Oral Presentations integrated with symposia where appropriate
- Official Poster Rounds held during morning breaks
- Wednesday 20 June — Trainees’ and Undergraduates’ Networking Boat Trip
- Thursday 21 June — Conference Dinner

---

**Important Deadline**

- Advance Registration Ends
- Monday 4 June 2018 (23.59 hrs)
07.20 pg 22 [Trajectum]
Registration and Coffee

07.20–18.00 pg 22 [Trajectum]
Slide Seminar Case Competition Viewing

08.15–08.30 pg 22 [Auditorium 2]
Welcome Address
Prof HI Grabsch, Maastricht

08.30–11.55 pg 22 [Auditorium 2]
Symposium (including Oral Presentations):
From Fixed to Functional Breast Pathology

09.45–10.35 Refreshment Break / Trade Exhibition [Trajectum]
Official Poster Rounds [Lobby]

12.10–12.55 pg 27 [Auditorium 2]
BDIAP Kristin Henry Lecture:
The Impact of Genetics on Renal Cancer Classification – Revisited
Prof S Fleming, Dundee, UK

12.55–13.00 pg 27 [Auditorium 2]
Presentation: Pathological Society Ritchie Medal
Presented to Prof S Fleming, Dundee, UK

13.00–14.00 pg 27
Lunch / Trade Exhibition [Trajectum]
Poster Viewing [Lobby]

13.05–13.50 pg 58 [Rome]
Industry Sponsored Lunchtime Symposium 1
Separate lunch will be provided

14.00–17.10 pg 30 [Auditorium 2]
Symposium (including Oral Presentations):
Rare Breast Cancers – From Microscope to Molecule

14.00–17.10 pg 27 [Rome]
Symposium (including Oral Presentations):
Early Colorectal Cancer – Bowel Cancer Screening

17.15–18.00 pg 31 [Auditorium 2]
Public Lecture: Making Surgery More Precise – Seeing a Tumour Faster Than Ever Before
Prof R Heeren, Maastricht, NL

18.30–20.30 pg 31 [Bonnenfanten Museum, Maastricht]
Networking Reception at the Bonnenfanten Museum
Co-sponsored by the Maastricht Convention Bureau
### Programme Overview

**Wednesday 20 June 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>[Trajectum]</td>
<td>Registration and Coffee</td>
</tr>
<tr>
<td>07.30–18.00</td>
<td>[Trajectum]</td>
<td>Slide Seminar Case Competition Viewing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Competition closes today at 18.00</td>
</tr>
<tr>
<td>08.30–11.50</td>
<td>[Auditorium 2]</td>
<td>Symposium (including Oral Presentations): Genotype or Phenotype – What Matters Most in Gastrointestinal Cancers?</td>
</tr>
<tr>
<td>09.40–10.30</td>
<td>[Trajectum]</td>
<td>Refreshment Break / Trade Exhibition</td>
</tr>
<tr>
<td></td>
<td>[Lobby]</td>
<td>Official Poster Rounds</td>
</tr>
<tr>
<td>12.05–12.50</td>
<td>[Auditorium 2]</td>
<td>Pathological Society Sir N Wright Lecture: Exploring Neutrophil Function to Delineate Novel Treatments in Acute Respiratory Distress Syndrome</td>
</tr>
<tr>
<td></td>
<td>[Auditorium 2]</td>
<td>Dr D Dorward, Edinburgh</td>
</tr>
</tbody>
</table>
| 12.50–14.00   | [Trajectum] | Lunch / Trade Exhibition /
|               | [Lobby]   | Poster Viewing                                                                                                                              |
| 13.05–13.50   | [Athens]  | Industry Sponsored Lunchtime Symposium 3                                                                                                       |
| 14.00–17.00   | [Auditorium 2] | Symposium (including Oral Presentations): Current Issues in Uterine Pathology for the Diagnostic Histopathologist  
|               | [Auditorium 2] | Jointly organised by Dr N Wilkinson and the Trainees’ Meetings Sub-Committee                                                               |
| 14.00–17.10   | [Athens]  | Symposium (including Oral Presentations): New Perspectives on Biliary Tract Disease                                                            |
| 15.10–15.40   | [Trajectum] | Refreshment Break / Trade Exhibition                                                                                                           |
|               | [Lobby]   | Poster Viewing                                                                                                                              |
| 18.00–20.00   | [Maaspromenade 38, Boat: Jekervallei] | Trainees’ and Undergraduates’ Networking Boat Trip (additional £10 fee applies)                                                                 |
|               |          | Buses will depart at 17.30                                                                                                                    |
| 08.30–11.50   | [Rome]   | Symposium: Renal Pathology – Thrombotic Microangiopathy: What Does the Renal Biopsy Add to Patient Management?                               |
| 09.50–10.10   | [Lobby]  | Refreshment Break / Trade Exhibition                                                                                                           |
|               | [Lobby]   | Official Poster Rounds                                                                                                                        |
| 08.30–12.00   | [Madrid]  | Undergraduates’ Day (including Oral Presentations): From Cradle to Grave                                                                   |
| 09.40–10.30   | [Trajectum] | Refreshment Break / Trade Exhibition                                                                                                           |
|               | [Lobby]   | Official Poster Rounds                                                                                                                        |
| 13.05–13.50   | [Rome]   | Industry Sponsored Lunchtime Symposium 3                                                                                                       |
| 14.00–17.00   | [Auditorium 2] | Symposium (including Oral Presentations): New Perspectives on Biliary Tract Disease                                                            |
| 14.00–17.30   | [Madrid]  | Undergraduates’ Day: From Cradle to Grave (continued)                                                                                         |
| 15.00–15.50   | [Trajectum] | Refreshment Break / Trade Exhibition                                                                                                           |
|               | [Lobby]   | Poster Viewing                                                                                                                              |

---

*See page number in Detailed Programme [Location in brackets]*
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>Trajectum</td>
<td>Registration and Coffee</td>
</tr>
<tr>
<td>08.30–12.00</td>
<td>Rome</td>
<td>Symposium: An Update on the Pathology of Prostate Cancer</td>
</tr>
<tr>
<td>09.40–10.30</td>
<td>Trajectum</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td></td>
<td>Trajectum</td>
<td>Trade Exhibition</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
<td>Official Poster Rounds</td>
</tr>
<tr>
<td>12.00–14.00</td>
<td>Trajectum</td>
<td>Lunch / Trade Exhibition</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>13.00–14.00</td>
<td>Berlin</td>
<td>Pathological Society Annual General Meeting</td>
</tr>
<tr>
<td>14.00–16.30</td>
<td>Auditorium 2</td>
<td>Plenary Oral Presentations</td>
</tr>
<tr>
<td>15.00–15.30</td>
<td>Trajectum</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td></td>
<td>Trajectum</td>
<td>Trade Exhibition</td>
</tr>
<tr>
<td></td>
<td>Lobby</td>
<td>Official Poster Rounds</td>
</tr>
<tr>
<td>16.20–16.50</td>
<td>Auditorium 2</td>
<td>Presentations and Awards</td>
</tr>
<tr>
<td>16.20–16.35</td>
<td></td>
<td>PALGA Award: Best Scientific Paper</td>
</tr>
<tr>
<td>16.35–16.50</td>
<td></td>
<td>Pathological Society Most Impactful Trainee Award</td>
</tr>
<tr>
<td>16.55–17.45</td>
<td>Auditorium 2</td>
<td>Pathological Society Doniach Lecture: Discovery Pathology and New Approaches to Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof JE Martin, London, UK</td>
</tr>
<tr>
<td>19.00</td>
<td>Grotten van Kanne, Reimst, Belgium</td>
<td>Conference Dinner</td>
</tr>
</tbody>
</table>

Outward buses will depart at 18.45. Return shuttle buses will be available from 23.00.
### Programme Overview

**Friday 22 June 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration and Coffee</td>
</tr>
<tr>
<td>09.00–12.25</td>
<td>The TEAF Oncology Chair Summit: <em>The Future of Cancer Management</em></td>
</tr>
<tr>
<td>10.25–10.55</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>12.25–13.35</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.35–16.45</td>
<td>The TEAF Oncology Chair Summit: <em>The Future of Cancer Management</em> (continued)</td>
</tr>
<tr>
<td>14.25–14.55</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>16.45</td>
<td>End of Conference</td>
</tr>
</tbody>
</table>

**Notice to Members**

Please ensure that all relevant information regarding this meeting is passed on to any non-members who wish to participate.
## REGISTRATION FEES

<table>
<thead>
<tr>
<th>Delegate Type (shown in bold)</th>
<th>Fee Category (shown in italic)</th>
<th>Early Bird</th>
<th>Advance</th>
<th>Late Booking</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDIA, IAP, NVVP or Pathological Society Member</td>
<td>Ordinary Member, Consultant and/or equivalent position</td>
<td>£135</td>
<td>£210</td>
<td>£230</td>
</tr>
<tr>
<td>BDIA, IAP, NVVP or Pathological Society Concessionary Member</td>
<td>Biomedical Scientist; Honorary or Senior Member; PhD Student; Post-Doctoral Fellow; Technician and Trainee</td>
<td>£45</td>
<td>£80</td>
<td>£100</td>
</tr>
<tr>
<td>Pathological Society Undergraduate Student Member</td>
<td>Undergraduate Student</td>
<td>Free</td>
<td>£30</td>
<td>£20</td>
</tr>
<tr>
<td>Non-Member</td>
<td>Consultant; Non-Training Grade; Career Grade; Staff; Senior Scientists and Clinicians</td>
<td>£190</td>
<td>£280</td>
<td>£300</td>
</tr>
<tr>
<td>Non-Member Concessionary</td>
<td>Biomedical Scientist; PhD Student; Post-Doctoral Fellow, Technician and Trainee</td>
<td>£60</td>
<td>£95</td>
<td>£115</td>
</tr>
<tr>
<td>Non-Member Undergraduate Student</td>
<td>Undergraduate Student</td>
<td>£60</td>
<td>£95</td>
<td>£115</td>
</tr>
</tbody>
</table>

### Early Bird Fees
- To qualify: register before 23.59 on Monday 14 May 2018

### Advance Fees
- To qualify: register after 00.01 on Tuesday 15 May 2018 but before 23.59 on Monday 4 June 2018

### Late Booking Fees
- For those who register after 00.01 on Tuesday 5 June 2018

### CONCESSIONS
Delegates from categories: **Non-Member Undergraduate Student** and **Non-Member Concessionary** must provide an identification document as proof of their student or trainee status, including National Training Number where applicable. Proof must be by way of a statement from the Head of Department (see below):

- A template document is available on our website: [www.path.org.uk](http://www.path.org.uk)
- Documents to be uploaded via the registration system.
PLENARY ORAL SESSION [Auditorium 2]
The seven highest-ranked abstracts will be presented on Thursday 21 June, 14.00–16.15.

Prize
A prize of £500 plus 12 bottles of Champagne will be awarded for the best Plenary Oral Presentation by the Journal of Pathology at the Conference Dinner.

POSTERS, VIEWING AND OFFICIAL ROUNDS [Lobby]
☆NEW☆ Official Poster Chairs will review the posters during the morning break on Tuesday, Wednesday and Thursday.

It is requested that posters should be in place by 09.00 hrs on Tuesday 19 June and remain on display until the end of Thursday 21 June 2018.

Poster Size
Poster boards will be landscape orientation, size 950 mm x 1360 mm. Please do not exceed these dimensions. Fixings will be provided.

For information on the poster printing service visit: www.path.org.uk

Viewing
Delegates are encouraged to visit the posters during break times as well as during the official rounds.

Formal Poster Viewing and Official Rounds
Tuesday 19 June 09.55–10.30
Wednesday 20 June 09.50–10.25
Thursday 21 June 09.50–10.25

Poster round chairs will be circulating during these times to select the winners of the following prizes. Every poster presenter is expected to give a three minute rapid-fire presentation of their poster to the official jury, and to answer questions.

POSTER PRIZES
BDIAP POSTER PRIZES
Prizes of £400, £300 and £200 will be awarded for the best three posters relevant to diagnostic pathology.

PATHOLOGICAL SOCIETY POSTER PRIZES
Pathological Society’s Sir Alastair Currie Prize (£400), second prize (£300) and third prize (£200) will be awarded for the best posters.

CAMBRIDGE UNIVERSITY PRESS PRIZES
Prizes (£100 book tokens) will be awarded for the best posters of Trainees and Undergraduates.

WINNERS
Winners will be announced at the Conference Dinner on Thursday 21 June 2018.

ORAL PRESENTATIONS
☆NEW☆ For Maastricht Pathology 2018 the oral presentations will be integrated into symposia sessions, where appropriate.

Presentations will be allocated 10 minutes each, to include discussion. These will be selected on the basis of the written abstracts. Those papers not selected for oral presentation will be required to be presented as posters.

Speakers are reminded that no communication may exceed the time allocated on the programme without the consent of the meeting, obtained through the Chairman.
POSTER PRESENTATIONS
Publication of abstracts in the Journal of Pathology On-Line Supplement
The presenting author (or another author) must attend their allocated poster round in order for the abstract to be published in the Journal of Pathology On-line Supplement.

SLIDE SEMINAR COMPETITION AND REVIEW SESSION
VIEWING (BEFORE THE MEETING)
Digital slide images of all cases are available for preview on the website in advance of the meeting. Please visit: https://oxford-brc.webmicroscope.com/Personal/MaastrichtPathology2018

VIEWING (DURING THE MEETING) [Internet Cafe, Trajectum]
Digital slide images of all cases will be available during the meeting at the Internet Cafe located in the Trajectum.

DISCUSSION SESSION
Thursday 21 June 2018.

PRIZE
A £250 Amazon Voucher.
The winner will be announced at the Conference Dinner on Thursday 21 June 2018.

Viewing Virtual Slides [Trajectum]
Slides images will be available for viewing on:
Tuesday 19 June 07.20–18.00
Wednesday 20 June 07.30–18.00 (Please note the competition closes on Wed 20 June at 18.00)

Competition
There will be a slide competition using digital slide images, which will be available during the days/times shown above and will be available online in advance of the meeting.

Competition Case Discussion Session [Lisbon]
Thursday 21 June 08.30–09.40

SYMPOSIA
Tuesday 19 June
08.30–11.55 [Auditorium 2] From Fixed to Functional Breast Pathology
08.30–11.55 [Rome] Advances in Lung Cancer Pathology and Management
08.30–11.50 [Berlin] The Future of Pathology
14.00–17.10 [Rome] Early Colorectal Cancer – Bowel Cancer Screening

Wednesday 20 June
08.30–11.50 [Auditorium 2] Genotype or Phenotype – What Matters Most in Gastrointestinal Cancers?
08.30–11.50 [Athens] On the Frontiers of Bone and Soft Tissue Tumours
08.30–11.50 [Rome] Renal Pathology – Thrombotic Microangiopathy: What Does the Renal Biopsy Add to Patient Management?
14.00–17.10 [Auditorium 2] Current Issues in Uterine Pathology for the Diagnostic Histopathologist Jointly organised by Dr N Wilkinson and the Trainees’ Meetings Sub-Committee
14.00–17.10 [Athens] New Perspectives on Biliary Tract Disease
14.00–17.10 [Rome] Renal Pathology – Macrophage Quantification in Glomerulonephritis: Should it be Routine Practice?

Thursday 21 June
08.30–12.00 [Berlin] Molecular Pathological Epidemiology (MPE) – Integrative Big-Data Population-Pathobiology
08.30–11.50 [Athens] Dermatopathology
08.30–12.00 [Rome] An Update on the Pathology of Prostate Cancer
12.00–13.00 [Lisbon] Mass Spectrometry Imaging – Possibilities in Pathology

Friday 22 June
09.00–16.45 [Auditorium 2] The TEFAF Oncology Chair Summit
TRAINED PROGRAMME
Tuesday 19 June
08.30–12.05 [Madrid]
Cytology

Thursday 21 June
08.30–12.00 [Lisbon]
Trainee's Session (including Slide Seminar Discussion)

UNDERGRADUATES' DAY
Wednesday 20 June
08.30–17.30 [Madrid]
From Cradle to Grave

★ NEW FOR MAASTRICHT ★

TRAINED AND UNDERGRADUATES’ NETWORKING BOAT TRIP
Wednesday 20 June 2018 (18.00–20.00). Please note: a £10 fee applies to this event. Boat located at Maaspromenade 58 (between St. Servas Bridge and Wilhelmina Bridge). Boat name: Jekervallei. Buses will depart at 17.30.

MEET THE EXPERTS LUNCH FOR PhD STUDENTS [MECC Cafe]
The TEFAF Oncology Chair Summit, Friday 22 June 2018 (12.35–13.35)
GROW has invited the speakers to participate in a “Meet the Experts Lunch”. Numbers are limited to 50 PhD students, separate registration required. GROW will allocate individual students to a particular speaker.

INDUSTRY SPONSORED LUNCHTIME SYMPOSIA
These four events will be held on:
1. Tuesday 19 June 2018 13.05–13.50 [Rome]
2. Wednesday 20 June 2018 13.05–13.50 [Athens]
3. Wednesday 20 June 2018 13.05–13.50 [Rome]

TRADE EXHIBITION
There will be a Trade Exhibition at the meeting held in the Trajectum, adjacent to the catering areas.

CONTINUING PROFESSIONAL DEVELOPMENT (CPD)

ROYAL COLLEGE OF PATHOLOGISTS
The Royal College of Pathologists has approved the Conference as detailed below.

UNITED KINGDOM CPD

Thursday 21 June 7 credits
Friday 22 June 5 credits

EUROPEAN CPD
Maastricht Pathology 2018, Maastricht, Netherlands, 19.06.2018–22.06.2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at:

www.ama-assn.org/education/earn-credit-participation-international-activities

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

Tuesday 19 June 7.00 credits
Wednesday 20 June 6.00 credits
Thursday 21 June 6.00 credits
Friday 22 June 5.00 credits

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.
TRAVELLING TO MAASTRICHT
For travel information please visit: www.path.org.uk

ACCOMMODATION
Discounted hotel accommodation has been reserved for delegates, please visit: www.path.org.uk

SOCIAL ACTIVITIES
TUESDAY 19 JUNE 2018
Networking Reception at Bonnenfanten Museum and Tour
Co-sponsored by the Maastricht Convention Bureau
For information about the Bonnenfanten Museum visit: www.bonnefanten.nl/en
Reserve your free ticket when registering online. Please visit: www.path.org.uk

THURSDAY 21 JUNE 2018
Conference Dinner
The Conference Dinner venue is Grotten van Kanne (deep inside a mountain in Belgium). For information about the venue please visit: www.grottenvankannevzw.be/index.html
Outward buses will depart at 18.45. Return shuttle buses will be available from 23.00.
Tickets are £60 (£80 if booked after 14 May) and £30 for Undergraduates.
Please reserve your ticket when registering online at: www.path.org.uk

LOCAL PLACES OF INTEREST
For information please visit: www.netherlands-tourism.com/maastricht

PRESENTATIONS
Presentation Checking and Preview
Presentation Checking and Preview facilities will be provided.

Oral Presentations/Lectures
Presentation format: Powerpoint only, must be PC compatible and must be on a USB. Presenters must attend their nominated lecture theatre 30 minutes before their presentation time.

INTERNET ACCESS
Free wireless access is available throughout the conference venue.
Laptop computers will be available.

MESSAGES
During the Meeting, messages for delegates may be left at the following telephone number: +44 (0)7964 024118.
There will also be a message board located beside the Registration Desk.

REFRESHMENTS
All refreshments will be served in the Trajectum unless stated otherwise.

BADGES
Delegates are requested to wear their badges at all times.

COATS AND BAGS
Facilities for coats and bags will be provided.

NOTICE TO MEMBERS
Please ensure that all relevant information regarding this meeting is passed on to any non-members who wish to participate.

DISCLAIMER
The British Division of the International Academy of Pathology, the Dutch Pathological Society (NVVP) and the Pathological Society of Great Britain & Ireland cannot be held responsible for any injury or loss sustained during the Meeting.

FURTHER INFORMATION
Any further information or amendments to this programme will be posted on the meeting website: www.path.org.uk
Please note all timings, titles and speakers are subject to alteration.
FUTURE MEETINGS

British Division of the IAP
2018 22 November, London
BDIAP–UKLPG: Liver Pathology Update Meeting
23–24 November, London
BDIAP–BSG: Symposium on Lower GI Pathology

Pathological Society
Second Joint Winter Meeting with The Royal Society of Medicine

Joint Meetings of the British Division of the IAP and the Pathological Society
2019 2–4 July, Harrogate
Leeds Pathology 2019

ABSTRACT REVIEWERS

Prof MJ Arends, Edinburgh  Dr G Kokai, Liverpool
Dr EW Benbow, Manchester  Dr B Loftus, Dublin
Prof DM Berney, London  Dr M Loughrey, Belfast
Dr T Brenn, Calgary  Dr S Manek, Oxford
Dr L Burke, Cork  Prof GI Murray, Aberdeen
Prof SS Cross, Sheffield  Dr N Pillay, London
Dr T Crotty, Dublin  Prof SE Pinder, London
Prof MQ Du, Cambridge  Prof CM Quinn, Dublin
Prof RM Feakins, London  Prof ISD Roberts, Oxford
Prof S Fleming, Dundee  Prof J Sluimer, Maastricht
Prof TR Helliwell, Liverpool  Prof G Thomas, Southampton
Prof CS Herrington, Edinburgh  Dr RM Tirabosco, London
Dr O Houghton, Belfast  Dr D Treanor, Leeds
Prof SG Hubscher, Birmingham  Prof P van der Valk, Amsterdam
Dr TS Jacques, London  Dr L Venkatraman, Belfast
Dr N Kirkham, Glasgow  Prof KP West, Leicester

GENERAL ARRANGEMENTS
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.20</td>
<td>REGISTRATION and COFFEE</td>
<td>Trajectum</td>
</tr>
<tr>
<td>07.20 – 18.00</td>
<td>SLIDE SEMINAR CASE COMPETITION VIEWING</td>
<td>Trajectum</td>
</tr>
<tr>
<td>08.15 – 08.30</td>
<td>WELCOME ADDRESS</td>
<td>Auditorium 2</td>
</tr>
<tr>
<td>08.30 – 11.55</td>
<td>SYMPOSIUM — including Oral Presentations</td>
<td>Auditorium 2</td>
</tr>
<tr>
<td>08.30–08.55</td>
<td>[S1] Impact of Pathology on Breast Cancer Patients</td>
<td>Dr JML Stouthard</td>
</tr>
<tr>
<td>08.55–09.20</td>
<td>[S2] Functional Pathology of ER Positive Breast Cancers</td>
<td>Dr W Zwart</td>
</tr>
<tr>
<td>09.20–09.45</td>
<td>[S3] High Quality Breast Pathology of Today and Challenges for Tomorrow</td>
<td>Dr JS Thomas</td>
</tr>
<tr>
<td>09.45–10.35</td>
<td>REFRESHMENT BREAK / TRADE EXHIBITION</td>
<td>[Trajectum]</td>
</tr>
<tr>
<td>10.35–11.00</td>
<td>Detection of Homologous Recombination Deficiency in Breast Cancer</td>
<td>Dr TG Meijer</td>
</tr>
<tr>
<td>11.00–11.25</td>
<td>Modern Breast Pathology: Don’t Forget About the Past, Live the Future</td>
<td>Dr J Wesseling</td>
</tr>
<tr>
<td>11.25–11.35</td>
<td>[O1] Raman Analysis of Breast Cancer: A Large Tissue Microarray Study</td>
<td>Prof Dr E-J Speel</td>
</tr>
<tr>
<td>11.35–11.45</td>
<td>[O2] Inter- and Intra-Laboratory Variation in the Histopathological Grading of Ductal Carcinoma In Situ of the Breast in a Nationwide Cohort in the Netherlands</td>
<td>Prof Dr E-J Speel</td>
</tr>
<tr>
<td>11.45–11.55</td>
<td>[O3] Prospective Verification of a Reverse Transcriptase qPCR Assay for Molecular Subtyping of Breast Cancers</td>
<td>Prof Dr E-J Speel</td>
</tr>
<tr>
<td>08.30 – 11.55</td>
<td>SYMPOSIUM — including Oral Presentations</td>
<td>Auditorium 2</td>
</tr>
<tr>
<td>08.30–08.55</td>
<td>[S4] Limitations of the 2015 WHO Classification of Lung Cancer</td>
<td>Dr E Thunnissen</td>
</tr>
<tr>
<td>08.55–09.20</td>
<td>[S5] Molecular Medicine in Lung Cancer: Insights in Molecular Pathogenesis Driving Better Therapies</td>
<td>Prof RB Büttner</td>
</tr>
<tr>
<td>09.20–09.45</td>
<td>[S6] Emerging Biomarkers for Immuno-Oncology in Lung Cancer</td>
<td>Prof KM Kerr</td>
</tr>
<tr>
<td>09.45–10.35</td>
<td>REFRESHMENT BREAK / TRADE EXHIBITION</td>
<td>[Trajectum]</td>
</tr>
</tbody>
</table>

References:
1. University of Sheffield, Sheffield, UK; 2. Queen Elizabeth Hospital Birmingham, Birmingham, UK; 3. University of Birmingham, Birmingham, UK; 4. School of Medical Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
5. UMC Utrecht, Utrecht, NL; 6. PALGA (The Dutch Nationwide Network and Registry of Histopathology and Cytopathology), Houten, NL.
7. MUMC+, Maastricht, NL; 8. Biontech Diagnostics GmbH, Mainz, Germany.
SYMPOSIUM: Advances in Lung Cancer Pathology and Management (continued)

10.35–11.00 [S7] New Insights in Molecular Pathology of Neuroendocrine Lung Tumours: A Multi-Omics Comparative Analysis
Dr L Fernandez-Cuesta
International Agency for Research on Cancer, Lyon, France

10.35–11.00 [S8] Hunting for Cancer Cells and Molecules in the Blood
Dr E Schuuring
UMC Groningen, Groningen, NL

S Waise; CJ Hanley; R Parker; CH Ottensmeier; MJ Rose-Zerilli; GJ Thomas
University of Southampton, Southampton, UK

H Dubbink; W Geurts-Giele; I Meijsen; C van der Leest; R Peric; J von der Thüsen; J Aerts; W Dinjens
1Erasmus MC Cancer Institute/Pathology, Rotterdam, NL; 2Erasmus Medical Center Cancer Institute/Pulmonary Diseases, Rotterdam, NL

11.35–11.45 [O6] Searching for Diagnostic Criteria in Pre-Operative Biopsy Specimen for Large Cell Neuroendocrine Carcinoma (LCNEC)
EJM Speel; JL Derks; RJ Van Suylen; MA Den Bakker; RA Damhuis; EC van den Broek; AC Dingemans; E Thunnissen
1MUMC+, Maastricht, NL; 2Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, NL; 3Maasstad Hospital, Rotterdam, NL; 4Comprehensive Cancer Association, Utrecht, NL; 5PALGA Foundation, Houten, NL; 6VUMC, Amsterdam, NL

SYMPOSIUM
The Future of Pathology
Chair: Prof GA Meijer, Netherlands Cancer Institute, Amsterdam, NL
Prof M van Engelund, Maastricht University Medical Center+, Maastricht, NL

08.30–09.05 [S9] National Scale Tumour Whole Genome Sequencing for Personalized Cancer Treatment in the Netherlands
Dr E Cuppen
Hartwig Medical Foundation, Amsterdam, NL
**Trainees’ Symposium: Cytology** (continued)
Chair: Dr A Chandra, Guys and St Thomas’ Hospital, London, UK
Dr R Dina, Hammersmith Hospital, Imperial College NHS Trust, London, UK

11.45–11.55  **[07]** PD-L1 Staining in Histologic and Cytological Material: Validation and Results
P Van der Valk; EJ Kooi; W Vos; M Ramkema; T Radonic
VUMC, Amsterdam, NL

11.55–12.05  **[08]** An Exquisitely Sensitive Method for Mutation Detection
JC Hassall; HO Ebili; M Ilyas
QMC/University of Nottingham, Nottingham Molecular Pathology Node, Nottingham, UK

**Poster Viewing and Official Rounds**

<table>
<thead>
<tr>
<th>Chair Group — Category</th>
<th>Poster Number</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 – Breast 1</td>
<td>P1–5</td>
<td>IO Ellis, Nottingham; L Kooreman, Maastricht</td>
</tr>
<tr>
<td>2 – Breast 2</td>
<td>P6–10</td>
<td>S Hauptmann, Maastricht; J Wesseling, Amsterdam</td>
</tr>
<tr>
<td>3 – Breast 3</td>
<td>P11–12*</td>
<td>V Speirs, Leeds; PJ van Diest, Utrecht</td>
</tr>
<tr>
<td></td>
<td>P14–15</td>
<td></td>
</tr>
<tr>
<td>4 – Cardiovascular/Pulmonary 1</td>
<td>P16–20 *</td>
<td>K Kerr, Aberdeen; E Thunissen, Amsterdam</td>
</tr>
<tr>
<td>5 – Cardiovascular/Pulmonary 2</td>
<td>P22–27 *</td>
<td>R Büttner, Cologne; AG Nicholson, London</td>
</tr>
<tr>
<td>6 – Gastrointestinal 1</td>
<td>P28–34</td>
<td>I Nagtegaal, Nijmegen; NP West, Leeds</td>
</tr>
<tr>
<td>7 – Gastrointestinal 2</td>
<td>P35–40</td>
<td>GG Hutchins, Leeds; A Lugli, Bern</td>
</tr>
<tr>
<td>8 – Gastrointestinal 3</td>
<td>P41–46</td>
<td>A De Bruyne, Venlo; NA Shepherd, Cheltenham</td>
</tr>
<tr>
<td>9 – Haematopathological Pathology</td>
<td>P47–53</td>
<td>RJ Byers, Manchester; MQ Du, Cambridge</td>
</tr>
<tr>
<td>10 – Neuropathology/Ophthalmic</td>
<td>P54–60</td>
<td>JE Martin, London; P van der Valk, Amsterdam</td>
</tr>
</tbody>
</table>

*Posters P21 and P26 have been withdrawn.
† For P13 refer to the table on page 47.
### Rome

**SYMPOSIUM: Early Colorectal Cancer – Bowel Cancer Screening**  
(continued)

- **14.00 – 17.10 — continued**
- **[S14] What Should We Do with Tumour Budding in Early CRC?**  
  Prof A Lugli  
  Institute of Pathology, University of Bern, Bern, Switzerland

**REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]**

**POSTER VIEWING [Lobby]**

- **15.50 – 16.15**  
  **[S15] Not So Simple Pathology: Issues from the Screening Programme**  
  Prof NA Shepherd  
  Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK

**16.15 – 16.40**  
**[S16] Implementation of a Nation Wide Strategy for MSI Testing: Challenges and Results**  
® Prof Dr MJL Ligtenberg; IE Fakkert; HW Willems; YK Peeks; S Langenveld; ID Nagtegaal; EM Leter; AR Mensenkamp; L Spruijt; N Hoogerbrugge

1. Department of Human Genetics and Department of Pathology, Radboud UMC, Nijmegen, NL; 2. Department of Human Genetics, Radboud UMC, Nijmegen, NL; 3. Department of Pathology, Radboud UMC, Nijmegen, NL; 4. Department of Clinical Genetics, MUMC+, Maastricht, NL

**16.40 – 17.00**  
**[O9] Comparison of Mutational Status in the EGFR Pathway Across Four Different Platforms in the Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative Therapy (FOXtROT) Trial**  
® AC Westwood; D Bottomley; GJ Hemmings; M Taylor; E Tinkler-Hundal; H Wood; K Marks; K Handley; L Magill; M Seymour; R Gray; D Morton; P Quirke; NP West

1. Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, UK; 2. Birmingham Clinical Trials Unit, University of Birmingham, UK; 3. St. James’s Institute of Oncology, University of Leeds, UK; 4. Nuffield Department of Population Health, University of Oxford, UK; 5. Department of Surgery, University of Birmingham, UK

**17.00 – 17.10**  
**[O11] NDRG4 is a Specific Enteric Neuronal Protein Which Attenuates Intestinal Tumour Progression and Protects Against Colitis-Induced Injury**  
N Vaes; G Rademakers; MJ Gijbels; KL Daenen; JRM Van der Meer; RMW Hofstree; W Boesmans; M van Engeland; ® V Melotte

1. MUMC+, Maastricht, NL; 2. Maastricht University, Maastricht, NL; 3. ErasmusMC, Rotterdam, NL; 4. LENS, TARGID, Department of Clinical and Experimental Medicine, KUL, Leuven, Belgium

### Berlin

**SYMPOSIUM**  
**The Pathology of Obesity**  
Chair: Dr C Peutz-Koostra, Maastricht University Medical Center+, Maastricht, NL  
Prof EAL Biessen, Maastricht University Medical Center+, Maastricht, NL

- **14.00 – 14.35**  
  **Microvascular Pathology in Obesity and Diabetes: Cause or Consequence?**  
  Dr AJHM Houben  
  Maastricht University, Maastricht, NL

- **14.35 – 15.10**  
  **Cardiovascular Pathology in the Obese**  
  Prof M Sheppard  
  St George’s University London, London, UK

**15.10 – 15.50**  
**REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]**  
**POSTER VIEWING [Lobby]**

- **15.50 – 16.20**  
  **[S17] Obesity and the Kidney**  
  Prof C Alpers  
  University of Washington Medical Center, Seattle, WA, USA

**16.20 – 16.45**  
**Liver Pathology in the Obese**  
Prof R Goldin  
Imperial College London, London, UK

**16.45 – 17.10**  
**NASH from Basic Knowledge to Future Therapy: Where do we Stand?**  
Prof Dr C Trautwein  
University Hospital Aachen, Aachen, Germany

---

### Symposium on Obesity

**Chair:**  
Dr C Peutz-Koostra, Maastricht University Medical Center+, Maastricht, NL  
Prof EAL Biessen, Maastricht University Medical Center+, Maastricht, NL

#### 14.00 – 14.35
**Microvascular Pathology in Obesity and Diabetes: Cause or Consequence?**  
Dr AJHM Houben  
Maastricht University, Maastricht, NL

#### 14.35 – 15.10
**Cardiovascular Pathology in the Obese**  
Prof M Sheppard  
St George’s University London, London, UK

#### 15.10 – 15.50
**REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]**  
**POSTER VIEWING [Lobby]**

#### 15.50 – 16.20
**Obesity and the Kidney**  
Prof C Alpers  
University of Washington Medical Center, Seattle, WA, USA

#### 16.20 – 16.45
**Liver Pathology in the Obese**  
Prof R Goldin  
Imperial College London, London, UK

#### 16.45 – 17.10
**NASH from Basic Knowledge to Future Therapy: Where do we Stand?**  
Prof Dr C Trautwein  
University Hospital Aachen, Aachen, Germany
14.00 – 17.10 — continued

SYMPOSIUM — including Oral Presentations
Rare Breast Cancers – From Microscope to Molecule
Chair: Prof V Speirs, University of Leeds, Leeds, UK
Prof PJ van Diest, Utrecht Medical Center, Utrecht, NL

14.00–14.35 [S12] Recent Advances in the Biology of Male Breast Cancer
Prof V Speirs
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

14.35–15.10 Metaplastic Breast Cancer
Dr R Natrajan
Institute of Cancer Research, London, UK

15.10–15.50 REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]

15.50–16.15 Phyllodes Breast Cancer
Prof PJ van Diest
UMC, Utrecht, NL

16.15–16.40 [S13] Inflammatory Breast Cancer Cells are Characterized by Attenuated SMAD Dependent TGFβ Signalling Leading to Impaired Cell Motility Responses
Dr SJ van Laere
University Antwerp / GZA Hospitals, Wilrijk, Belgium

16.40–16.50 [O12] Categorical Assessment of Stromal Inflammation in Ductal Carcinoma in Situ of the Breast Results in Substantial Interrater Reliability
® MR Van Bockstal1; M Baldewijns2; C Colpaert3; H Dano4; G Floris5; C Galant6; K Lambein6; D Peeters7; SM Van Renterghem8; AS Van Rompuy9; SLJ Verbeke9; S Verschueren9; J Van Dorpe9
1Erasmus MC, Rotterdam, NL; 2Antwerp University Hospital, Antwerp, Belgium; 3GZA, Antwerp, Belgium; 4University Clinics St Luc, Brussels, Belgium; 5Leuven University Hospitals, Leuven, Belgium; 6AZ St Lucas Hospital, Ghent, Belgium; 7Ghent University Hospital, Ghent, Belgium; 8AZ Delta, Roeselare, Belgium

16.50–17.00 [O13] The Cooperative Expression of the Solute Carriers, SLC1A5, SLC7A5 and SLC3A2, Confers a Poor Prognosis in the Highly Proliferative ER+ Breast Cancer Subtype
R El Ansari1; ML Craze1; D Soria2; M Diez-Rodriguez1; CC Nolan1; IO Ellis1; EA Rakha1; ® AR Green1
1University of Nottingham, Nottingham, UK; 2University of Westminster, London, UK

17.00–17.10 [O14] Assessment of Tumour Microenvironment Immune Cell Profile in Inflammatory Breast Carcinoma Using Digital Multiplex Analysis
® NM Badr1; F Berditchevski2; NY Asaad3; MM Abd Elwahed4; AG Abdou5; MM Serag El-Din6; F Hoar7; D Rea8; G Baldwin8; Y Horimoto6; N Sharma9; AM Shaaban10
1University of Birmingham and Menoufia University, Birmingham, UK; 2University of Birmingham, Birmingham, UK; 3Menoufia University, Menoufia, Egypt; 4City Hospital, Birmingham, UK; 5Queen Elizabeth Hospital, Birmingham, UK; 6Juntendo University, Tokyo, Japan; 7Leeds Teaching Hospitals, Leeds, UK; 8University of Birmingham and Queen Elizabeth Hospital, Birmingham, UK

17.15 – 18.00

PUBLIC LECTURE
Chair: Prof HI Grabsch, Maastricht University Medical Center+, Maastricht, NL
Making Surgery More Precise – Seeing a Tumour Faster Than Ever Before
Prof R Heeren
M4I, Maastricht University, Maastricht, NL

18.30 – 20.30

NETWORKING RECEPTION
Co-Sponsored by the Maastricht Convention Bureau
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>REGISTRATION and COFFEE</td>
<td>Trajectum</td>
<td></td>
</tr>
<tr>
<td>07.30 – 18.00</td>
<td>SLIDE SEMINAR CASE COMPETITION VIEWING</td>
<td>Trajectum</td>
<td>Competition closes today at 18.00</td>
</tr>
<tr>
<td>08.30 – 11.50</td>
<td>SYMPOSIUM — including Oral Presentations</td>
<td>Auditorium 2</td>
<td><strong>Genotype or Phenotype – What Matters Most in Gastrointestinal Cancers?</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Prof HI Grabsch, Maastricht University Medical Center+, Maastricht, NL</td>
<td></td>
<td><strong>Prof RFT McMahon, Manchester Royal Infirmary and University of Manchester, Manchester, UK</strong></td>
</tr>
<tr>
<td>08.30 – 09.05</td>
<td>[S18] Hereditary GI Cancer Syndromes</td>
<td></td>
<td><strong>Prof F Carneiro</strong> IPATIMUP, Porto, Portugal</td>
</tr>
<tr>
<td>09.05 – 09.40</td>
<td>JAPANESE SOCIETY OF PATHOLOGY GUEST LECTURE</td>
<td></td>
<td><strong>Recent Advances in Molecular Carcinogenesis of Colorectal Tumours</strong></td>
</tr>
<tr>
<td></td>
<td>Prof T Sugai Iwate Medical University, Morioka, Japan</td>
<td></td>
<td><strong>Prof T Sugai Iwate Medical University, Morioka, Japan</strong></td>
</tr>
<tr>
<td>09.40 – 10.30</td>
<td>REFRESHMENT BREAK / TRADE EXHIBITION (Trajectum)</td>
<td></td>
<td><strong>Immune Homeostasis in the Upper Gastrointestinal Tract</strong></td>
</tr>
<tr>
<td></td>
<td>[Lobby] — See page 35 for details</td>
<td></td>
<td><strong>Prof A Quas University of Cologne, Cologne, Germany</strong></td>
</tr>
<tr>
<td>10.30 – 10.55</td>
<td>[S19] Genotype or Phenotype: What Matters Most in Barrett’s Oesophagus?</td>
<td></td>
<td><strong>Prof R Langer Institute of Pathology, University of Bern, Bern, Switzerland</strong></td>
</tr>
<tr>
<td>10.55 – 11.20</td>
<td>[S20] Vascular Tumours of Soft Tissue and Bone</td>
<td></td>
<td><strong>Prof S Verbeke UZ Ghent, Ghent, Belgium</strong></td>
</tr>
<tr>
<td>11.20 – 11.30</td>
<td>[O15] An Assessment of EGFR Pathway Mutations in Late Stage Colorectal Cancer by Next Generation Sequencing in a Regional NHS Genomic Testing Service</td>
<td></td>
<td><strong>Prof R Sciot University Hospital, University of Leuven, Leuven, Belgium</strong></td>
</tr>
<tr>
<td>11.30 – 11.40</td>
<td>[O16] Histopathologist Features Predictive of Diagnostic Concordance at Expert Level Amongst a Large International Sample of Pathologists Diagnosing Barrett’s Dysplasia</td>
<td></td>
<td><strong>Prof R Sciot University Hospital, University of Leuven, Leuven, Belgium</strong></td>
</tr>
<tr>
<td></td>
<td>[O17] Defining the Clinical Value of Pathological Lymph Node Status and Primary Tumour Regression Grading Following Neoadjuvant Therapy in Oesophageal Cancer: Results from the MRC OE02 Trial</td>
<td></td>
<td><strong>Prof GGA Hutchins1; N Davarzani2; NP West3; L Hewitt4; M Nankivell5; D Cunningham6; WH Allum5; E Smyth5; N Valeri5; RE Langley5; HI Grabsch3</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Prof HI Grabsch, Maastricht University Medical Center+, Maastricht, NL</td>
<td></td>
<td><strong>1University of Leeds, Leeds, UK; 2Maastricht University, Maastricht, NL; 3Maastricht University Medical Centre, Maastricht, NL; 4University College London, London, UK; 5Royal Marsden Hospital, London, UK; 6Institute of Cancer Research, London, UK</strong></td>
</tr>
</tbody>
</table>

---

**Additional Information:**

- [www.path.org.uk](http://www.path.org.uk) for abstracts
- [00] = Abstract Number  [P] = Presenter
**SYMPOSIUM: On the Frontiers of Bone and Soft Tissue Tumours**

(continued)

**[O19]** Recurrent FN1 and/or ACVR2A Fusion Genes are Implicated in the Pathogenesis of Synovial Chondromatosis, Chondrosarcoma Secondary to Synovial Chondromatosis, and Soft Tissue Chondroma

- L Perez-Casanova
- H Ye
- AC Strobl
- F Berisha
- MF Amary
- N Pillay
- D Baumhoer
- R Tirabosco
- AM Flanagan

1Royal National Orthopaedic Hospital NHS Trust, London, UK
2Cancer Institute, University College London, London, UK
3Bone Tumor Reference Center, Institute of Pathology, University Hospital Basel, Basel, Switzerland

**[O20]** Development of a Novel FISH Probe for Detection of 1p/19q Codeletion in Routine Glioma Diagnosis

- K Satomi
- K Yamasaki
- A Yoshida
- S Wakai
- Y Matsushita
- Y Narita
- T Komori
- R Nishikawa
- K Ueki
- K Ichimura

1National Cancer Centre Hospital, Tokyo, Japan
2Osaka City General Hospital, Osaka, Japan
3Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
4Saitama Medical University International Medical Centre, Saitama, Japan
5Dokkyo University School of Medicine, Tochigi, Japan
6National Cancer Centre Research Institute, Tokyo, Japan

**SYMPOSIUM**

Renal Pathology – Thrombotic Microangiopathy: What Does the Renal Biopsy Add to Patient Management?

**Chair:** Prof HT Cook, Imperial College London, London, UK

**Prof ISD Roberts, John Radcliffe University Hospital, Oxford, UK**

**08.30–08.45**

*Introduction and Definitions*

Prof ISD Roberts
John Radcliffe University Hospital, Oxford, UK

**08.45–09.10**

*TMA: The German Experience*

Dr T Wiech
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

**09.10–09.35**

*TMA: Clinicopathological Correlations*

Prof HT Cook
Imperial College London, London, UK

**09.35–09.50**

*Discussion*

**09.50–10.30**

*REFRESHMENT BREAK / TRADE EXHIBITION* [Trajectum]

**OFFICIAL POSTER ROUNDS** [Lobby] — See page 35 for details

**09.50 – 10.25**

**POSTER VIEWING and OFFICIAL ROUNDS**

<table>
<thead>
<tr>
<th>CHAIR GROUP — CATEGORY</th>
<th>POSTER NUMBER</th>
<th>CHAIR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11 – Gastrointestinal 4</strong></td>
<td>P62–67 *</td>
<td>Prof RFT McMahon, Manchester; Prof P Quirke, Leeds</td>
</tr>
<tr>
<td><strong>12 – Gastrointestinal 5</strong></td>
<td>P68–73</td>
<td>Dr M Loughrey, Belfast; Prof R Langer, Bern</td>
</tr>
<tr>
<td><strong>13 – Gastrointestinal 6</strong></td>
<td>P74–79</td>
<td>Prof R Feakins, London; Prof HI Grabsch, Maastricht</td>
</tr>
<tr>
<td><strong>14 – Gynaecological 1</strong></td>
<td>P80–84</td>
<td>Dr N Wilkinson, London; Dr N Orsi, Leeds</td>
</tr>
<tr>
<td><strong>15 – Gynaecological 2</strong></td>
<td>P85–89</td>
<td>Prof T Bosse, Leiden; Prof CS Herrington, Edinburgh</td>
</tr>
<tr>
<td><strong>16 – Gynaecological 3</strong></td>
<td>P90–94</td>
<td>Dr S Croce, Bordeaux; Dr K Vroobel, London</td>
</tr>
<tr>
<td><strong>17 – Hepatobiliary/Pancreas</strong></td>
<td>P95–99</td>
<td>Prof R Goldin, London; Prof SG Hubscher, Birmingham</td>
</tr>
<tr>
<td><strong>18 – Renal</strong></td>
<td>P100–101</td>
<td>Dr K Amann, Erlangen; Prof ISD Roberts, Oxford</td>
</tr>
<tr>
<td><strong>19 – Ostearticular/Soft Tissue</strong></td>
<td>P102–103</td>
<td>Prof C Antonescu, New York; Prof C Fisher, London</td>
</tr>
</tbody>
</table>

* Poster P61 has been withdrawn.
Undergraduate Oral Presentation 3
[P63] Largest Negative Lymph Node Diameter: A Novel Predictor of Good Prognosis in Patients with Oesophageal Cancer
© M Kloft; J Ruisch; G Raghuram; G Fazzi; HI Grabsch
1Dept of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, NL; 2Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

Undergraduate Oral Presentation 4
[P94] Analysing the Epidemiology of Molar Pregnancies in England
© JJ Lewis; J Pawade
1University of Bristol, Southport, UK; 2Southmead Hospital, Bristol, UK

Undergraduate Oral Presentation 5
[P65] Towards High-Throughput Lymphocyte Quantification in Haematoxylin Eosin Stained Biopsy Sections by Establishing an Image Analysis Pipeline
© M Häller; GE Fazzi; E Clarke; DR Magee; HI Grabsch
1Dept of Pathology GROW School for Oncology and Developmental Biology, MUMC+, Maastricht, NL; 2Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; 3School of Computing, University of Leeds / HeteroGenius Limited, Leeds, UK

Best Undergraduate Oral Presentation Prizes

12.05 – 12.50
Auditorium 2
THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND SIR N WRIGHT LECTURE
Chair: Dr RJ Byers, General Secretary, Pathological Society; University of Manchester, Manchester, UK

[S27] Exploring Neutrophil Function to Delineate Novel Treatments in Acute Respiratory Distress Syndrome
Dr DA Dorward
Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

12.50 – 14.00
LUNCH / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]
14.00 – 17.10 — continued

P A Naiki-Ito¹; H Kato²; S Suzuki²; Y Yamashita²; S Takahashi²
¹Nagoya City University Graduate School of Medical Sciences/ Nagoya City East Medical Centre, Nagoya, Japan; ²Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

16.50–17.00 [O22] Rapid Evaporative Ionization Mass Spectrometry to Differentiate Between Normal Liver and Tumour Tissues
PM Vaysse¹; HI Grabsch²; J de Vos-Geelen³; SWM Olde Damink⁴; RMA Heeren¹; T Porta¹
¹Maastricht Multimodal Molecular Imaging (M4I) Institute, Maastricht University, Maastricht, NL; ²Department of Pathology, MUMC+, Maastricht, NL; ³Department of Internal Medicine, Division of Medical Oncology, MUMC+, Maastricht, NL; ⁴Department of Surgery, MUMC+, Maastricht, NL

17.00–17.10 [O23] Mutation Screening Using Formalin-Fixed Paraffin-Embedded Tissues: A Stratified Approach According to DNA Quality
F Cucco¹; A Clipson¹; H Kennedy¹; JS Thompson¹; M Wang¹; S Barrans²; M Van Hoppe³; E Ochoa Ruiz³; J Caddy³; D Hamid³; T Cummin³; C Burton³; AJ Davies³; P Johnson³; M Van Hoppe²; ሠMQ Du¹
¹Department of Pathology, University of Cambridge, Cambridge, UK; ²HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK; ³Southampton Clinical Trials Unit, University of Southampton, Southampton, UK; ⁴Cancer Research UK Clinical Centre, University of Southampton, Southampton, UK

14.00 – 17.10 Athens

SYMPOSIUM — including Oral Presentations
New Perspectives on Biliary Tract Disease
Chair: Prof R Goldin, Imperial College London, London, UK
Dr J Verheij, Academic Medical Center, Amsterdam, NL

14.00–14.25 [S28] General Clinical Introduction in Hepatobiliary Disease
Dr J de Bruijne
UMC Utrecht, Utrecht, NL

14.25–14.50 Clinicopathological Features of Biliary Neoplasms
Dr M Komuta
Cliniques Universitaires Saint-Luc, Brussels, Belgium

14.50–15.15 [S29] Scoring Systems for Liver Disease, Their Relevance and New Developments in Scoring Biliary Diseases
Prof SG Hubscher
University of Birmingham, Birmingham, UK

15.15–15.50 REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum] POSTER VIEWING [Lobby]

15.50–16.15 Drug Induced Liver Injury
Prof R Goldin
Imperial College London, London, UK

16.15–16.40 [S30] IgG4-Associated Cholangitis
Dr J Verheij
AMC, Amsterdam, NL
SYMPOSIUM — including Oral Presentations

Current Issues in Uterine Pathology for the Diagnostic Histopathologist
Jointly organised by Dr N Wilkinson and the Trainees’ Meetings Sub-Committee
Chair: Dr K Allen, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Dr N Wilkinson, University College London Hospitals Foundation Trust, London, UK

14.00–14.35 [S31] What’s New and Important in Reporting of Uterine Cancers
Dr KM Vroobel
The Royal Marsden NHS Foundation Trust, London, UK

14.35–15.10 Advances in the Molecular Aspects of Endometrial Cancer
Dr T Bosse
LUMC, Leiden, NL

15.10–15.40 REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]

15.40–16.15 An Update of Uterine Mesenchymal Tumours
Dr S Croce
Institut Bergonié, Bordeaux, France

16.15–16.40 [S32] Challenging Cases in Uterine Pathology
Dr N Wilkinson
University College London Hospitals Foundation Trust, London, UK
Chair: Dr S Croce, Institut Bergonié, Bordeaux, France
Dr N. Wilkinson, University College London Hospitals Foundation Trust, London, UK

Dr GF Konings1; KMC Cornel1; S Xanthoulea1; B Delvoux1; N Saarinen1; L Kooreman1; P Koskimies2; C Krakstad2; KE Fasmr3; IS Haldorsen3; MR Häkkinen4; S Auriola5; L Dubois1; N Lieuwes1; F Verhaegen1; LEJ Schyns1; HB Salvesen2; AJ Groot1; MY Bongers1; RFP Kruitwagen1; A Romano1
1MUMC+, Maastricht, NL; 2Forendo Pharma, Turku, Finland; 3Haukeland University Hospital, Bergen, Norway; 4University of Eastern Finland, Kuopio, Finland

16.50–17.00 [O26] Placental Maternal Vascular Malperfusion Lesions in Relation to Doppler Velocimetry in Pregnancies Complicated by Placenta Syndrome
Dr LAP Evers1; V Schiffer2; C Severens-Rijvers1; M Spaanderman1; S Al-Nasiry1
MUMC+, Maastricht, NL

SYMPOSIUM — including Oral Presentations
Renal Pathology – Macrophage Quantification in Glomerulonephritis: Should it be Routine Practice?
Chair: Prof HT Cook, Imperial College London, London, UK
Prof ISD Roberts, John Radcliffe University Hospital, Oxford, UK

14.00–14.25 Lupus Nephritis
Dr K Amann
Friedrich-Alexander University, Erlangen, Germany

14.25–14.50 IgA Nephropathy
Dr M Soares
John Radcliffe University Hospital, Oxford, UK

15.00–17.00 Placental Maternal Vascular Malperfusion Lesions in Relation to Doppler Velocimetry in Pregnancies Complicated by Placenta Syndrome
Dr LAP Evers1; V Schiffer2; C Severens-Rijvers1; M Spaanderman1; S Al-Nasiry1
MUMC+, Maastricht, NL
SYMPOSIUM: Renal Pathology – Macrophage Quantification in Glomerulonephritis: Should it be Routine Practice? (continued)

17.00–17.10 [O29] Peritubular Capillary Loss is Induced in the First Month After Transplantation by Ischemic and Allo-Immune Injury

AA Keijbeck1; FME Steegh1; MAC Gelens2; LWE van Heurn3; EAL Biessen1; MHL Christiaans2; CJ Peutz-Kootstra1

1Dept of Pathology, MUMC+, Maastricht, NL; 2Dept of Internal Medicine, MUMC+, Maastricht, NL; 3Department of Surgery, Academic Medical Centre, Amsterdam, NL

UNDERGRADUATES’ DAY — CONTINUED
From Cradle to Grave
Chair: Prof MJ Arends, Chair, Research Sub-Committee, Pathological Society, London; University of Edinburgh, Edinburgh, UK
Miss L Willems, Maastricht University, Maastricht, NL

14.00–14.05 Pathological Society Undergraduate Essay Prize Competition: Presentation to Winner — Mr S Seth

14.05–14.30 [S33] Why is Cancer a Disease of Old People and Sometimes of Children?
Prof JHJ van Krieken
Radboud University, Nijmegen, NL

Dr HIL Jacobs
Maastricht University and Harvard Medical School/MGH, Maastricht, NL

Prof B Kubat
MUMC, Netherlands Forensic Institute, Maastricht, NL

15.20–15.50 REFRESHMENT BREAK / TRADE EXHIBITION

15.50–17.30 Workshop: Hands-on Forensic Pathology
Chair: Dr BGH Latten, MUMC+, Maastricht, NL
Participants registered for the workshop will meet at 15.40 at the Registration Desk and walk together over to the Hospital’s Autopsy Room.

TRAINEES’ AND UNDERGRADUATES’ NETWORKING BOAT TRIP
(Additional £10 fee applies)

Boat located at Maaspromenade 58 (between St. Servas Bridge and Wilhelmina Bridge). Boat name: Jekervallei.

Buses will depart at 17.30.
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30</td>
<td>Trajectum</td>
<td>Registration and Coffee</td>
</tr>
<tr>
<td>08.30 – 11.50</td>
<td>Berlin</td>
<td>Symposium — Molecular Pathological Epidemiology (MPE): Integrative Big-Data Population-Pathobiology Chair: Prof PA van den Brandt, Maastricht University, Maastricht, NL Second Chair to be confirmed</td>
</tr>
</tbody>
</table>
| 08.30–09.05  | Berlin   | MPE Transforms Pathology: Integrating Genomics, Microbiome and Immunology
Prof S Ogino
Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA |
| 09.05–09.40  | Berlin   | Aspirin, Statins and MPE of Colon Cancer
Dr MB Loughrey; HG Coleman
Royal Victoria Hospital, Queen’s University Belfast, Belfast, UK; Queen’s University Belfast, Belfast, USA |
| 09.40–10.30  | Berlin   | Refreshment Break / Trade Exhibition — See page 47 for details |
| 10.30–11.05  | Berlin   | Official Poster Rounds — See page 47 for details |
| 10.30–10.55  | Athens   | Symposium — including Oral Presentations
Dermatopathology
Chair: Prof WJ Mooi, VU Medical Center Amsterdam, Amsterdam, NL
Prof A zur Hausen, Maastricht University, Maastricht, NL |
| 08.30–08.55  | Athens   | S39 Reactive Epidermal and Dermal Changes in Melanocytic Tumours
Prof WJ Mooi |
| 09.05–09.20  | Athens   | S40 Nevoid Pigment Cell Lesions
Dr JJ van den Oord
University Hospitals, KU Leuven, Leuven, Belgium |
| 09.20–09.45  | Athens   | Soft Tissue Tumours of the Skin
Dr T Brenn
Cumming School of Medicine, University of Calgary, Calgary, Canada |
| 09.45–10.30  | Athens   | Refreshment Break / Trade Exhibition — See page 47 for details |
| 10.30–10.55  | Athens   | Cutaneous Adnexal Tumours
Prof D Kazakov
Charles University Medical Faculty Hospital, Pilsen, Czech Republic |
| 10.55–11.20  | Athens   | S41 New Melanoma Syndromes: BAP1 and Beyond – Impact on the Pathologist
Dr T Wiesner
Medical University of Vienna, Vienna, Austria |
| 11.20–11.30  | Athens   | S30 Prognostic Value of Nkx2.1 Expression in Malignant Melanoma and Potential Implication on Patient Management
Prof S Elsheikh; I Kouzoukakis; C Fielden; T Pereira Raposo; M El-Tanani; M Ilyas
Nottingham University Hospital, Nottingham, UK; University of Nottingham, Nottingham, UK; University of Bradford, Bradford, UK |
| 11.30–11.40  | Athens   | O31 Early B Cell Gene Expression Pattern in Merkel Cell Carcinoma
Prof E Chteinberg; D Rennspiess; AM Haugg; V Winnepeppeninkx; EJ Speel; AK Kurz; M Zenke; A zur Hausen
MUMC+, Maastricht, NL; RWTH Aachen University Hospital, Aachen, Germany |
**Symposium: Dermatopathology (continued)**

11.40–11.50

**[032]** The Use of PD1 and PDL1 as Prognostic Markers in Malignant Melanoma

P S Elsheikh; A Wignall
Nottingham University Hospital, Nottingham, UK

**Symposium — including Oral Presentations**

**An Update on the Pathology of Prostate Cancer**

Chair: Dr L Browning, John Radcliffe Hospital, Oxford, UK
Dr M Varma, University Hospital of Wales, Cardiff, UK

08.30–09.05

**[S42]** Prostate Cancer Staging and Datasets: The Nitty-Gritty

Prof DM Berney
Barts Health NHS Trust, London, UK

09.05–09.40

**[S43]** Intraductal Carcinoma of the Prostate

Dr M Varma
University Hospital of Wales, Cardiff, UK

09.40–10.30

**Refreshment Break / Trade Exhibition**

**Official Poster Rounds**

[Lobby] — See page 47 for details

10.30–11.00

**[S44]** Prostate Cancer: Update on Gleason Grading

Dr A van Leenders
Erasmus Medical Center, Rotterdam, NL

11.00–11.30

**Molecular Pathology and Biomarkers of Prostate Cancer**

Prof G Kristiansen
University Hospital of Bonn, Bonn, Germany

11.30–11.40

**[O33]** Sequencing Older Archived FFPE DNA: First-Hand Experience and Potential Pitfalls

P JAA van de Pol1; P Ferronika2; MM Terpstra2; PA van den Brandt1; M van Engeland3; K Kok1; LJ Schouten1
1Dept of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, NL; 2Dept of Genetics, University of Groningen, UMC Groningen, Groningen, NL; 3Dept of Pathology, GROW-School for Oncology and Developmental Biology, MUMC+, Maastricht, NL

**Poster Viewing and Official Rounds**

<table>
<thead>
<tr>
<th>Chair Group — Category</th>
<th>Poster Number</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 — Autopsy / Forensic</td>
<td>P104–108</td>
<td>Prof S Fleming, Dundee; Prof B Kubat, Maastricht</td>
</tr>
<tr>
<td>21 — Cellular / Molecular Pathology 1</td>
<td>P109–113 *</td>
<td>Dr RJ Byers, Manchester; Prof M Ilyas, Nottingham</td>
</tr>
<tr>
<td>22 — Breast Experimental Tumour Pathology Technical Advances 1</td>
<td>P145–146</td>
<td>Prof MJ Arends, Edinburgh; Dr V Melotte, Maastricht</td>
</tr>
<tr>
<td>23 — Technical Advances 2</td>
<td>P147–152</td>
<td>Prof GI Murray, Aberdeen; Prof E-J Speel, Maastricht</td>
</tr>
<tr>
<td>24 — Education and Audit</td>
<td>P118–121 *</td>
<td>Dr L Browning, Oxford; Dr V Winnepenninckx, Maastricht</td>
</tr>
<tr>
<td>25 — Genitourinary 1</td>
<td>P122–127 *</td>
<td>Prof D Berney, London; Dr M Varma, Cardiff</td>
</tr>
<tr>
<td>26 — Genitourinary 2 Neonatal / Paediatric</td>
<td>P129–131</td>
<td>Dr G Kristiansen, Bonn; Dr E Villamar, Maastricht</td>
</tr>
<tr>
<td>27 — Head and Neck Skin 1</td>
<td>P132–134</td>
<td>Dr N Kirkham, Livingston; Prof A zur Hausen, Maastricht</td>
</tr>
<tr>
<td>28 — Skin 2</td>
<td>P139–142 *</td>
<td>Prof T Brenn, Calgary; Dr T Wiesner, Vienna</td>
</tr>
</tbody>
</table>

*Posters P110, P114, P115, P119, P120, P126, P143 and P144 have been withdrawn.*
08.30–09.40  CASE COMPETITION SLIDE SEMINAR DISCUSSION
Chair: Dr A Westwood, St James’s University Hospital, Leeds, UK
Dr C Young, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

08.30–08.38  Case 1
Dr K Allen
Leeds Teaching Hospitals NHS Trust, Leeds, UK

08.40–08.48  Case 2
Dr BGH Latten
MUMC+, Maastricht, NL

08.50–08.58  Case 3
Dr A van der Leden
MUMC+, Maastricht, NL

09.00–09.08  Case 4
Dr J van Heusden
MUMC+, Maastricht, NL

09.10–09.18  Case 5
Dr K Griffin
St James’s University Hospital, Leeds, UK

09.20–09.28  Case 6
Dr J Griffin
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

09.40–10.30  REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
OFFICIAL POSTER ROUNDS (Lobby) — See page 47 for details

10.30–11.00  JOINT PRESENTATION
[545] Standards of Training in Pathology Across Europe: Results from an International Survey
© Dr M Urbanowicz¹; BGH Latten²; D Pinto³; F Bosman⁴
¹European Organisation for Research and Treatment of Cancer (EORTC), European Society of Pathology (ESP), Brussels, Belgium; ²MUMC+, Maastricht, NL; ³Centro Hospitalar de Lisboa Ocidental, EPE, Nova Medical School, Lisboa, Portugal; ⁴Emeritus Professor of Pathology, University of Lausanne Medical Center, Lausanne, Switzerland

[546] Standards of Training in Pathology Across Europe: Results from an International Survey
© Dr D Pinto⁵; M Urbanowicz⁶; FT Bosman⁷
⁵Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa, Portugal; ⁶Medical Dept., EORTC, Brussels, Belgium; ⁷Lausanne University Hospital | CHUV, Lausanne, Switzerland

11.00–12.00  PANEL DISCUSSION
Prof F Bosman
CHUV, Lausanne, Switzerland

Prof C Cuvelier
Department of Medical and Forensic Pathology, Ghent University, Ghent, Belgium

Dr D Pinto
Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal

Prof P Quirke
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

Prof P van der Valk
VUMC, Amsterdam, NL

Dr C Young
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
DETAILED PROGRAMME Thursday 21 June 2018

12.00 – 14.00

LUNCH / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]

12.10 – 13.05

Lisbon

SYMPOSIUM
Mass Spectrometry Imaging – Possibilities in Pathology
Chair: Dr B Balluff, Maastricht University, Maastricht, NL
Dr T Porta, Maastricht University, Maastricht, NL

12.10–12.30
MALDI Imaging – Possibilities in Pathology
Dr K Schwamborn
TU, Munchen, Germany

12.30–12.50
Imaging Mass Microscope – A New Tool for Tissue Analysis in Clinical Research
Dr A-C Niehoff
Shimadzu, Duisburg, Germany

12.50–13.05
Data Analysis Strategies for Managing Large Cohorts of MS Imaging Studies
Dr D Trede
SCILS, Bremen, Germany

13.00 – 14.00

Berlin

THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND ANNUAL GENERAL MEETING
(Agendas will be sent to Members)

DETAILED PROGRAMME Thursday 21 June 2018

14.00 – 16.30

Auditorium 2

PLENARY ORAL PRESENTATIONS
Chair: Prof AM Flanagan, UCL Cancer Institute, London, UK
Prof ISD Roberts, John Radcliffe University Hospital, Oxford, UK

14.00–14.15
[PL1] Histological Features of Neoadjuvant Endocrine Therapy Response and Effect on Tumour Phenotype in Luminal Breast Cancer
© AM Shaaban1; N Badr2
1Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK;
2University of Birmingham, Birmingham, UK

14.15–14.30
[PL2] Investigating Stromal-Epithelial Interactions Using a Novel 3D Breast Cancer Organoid Model: Regulation of the Basal Epithelial Phenotype by Cancer-Associated Fibroblasts
© CJ Hanley3; GJ Thomas4; AJ Ewald5
3University of Southampton, Southampton, UK; 4Johns Hopkins, Baltimore, USA

14.30–14.45
[PL3] Copy Number Signatures Elucidate Mechanisms Underlying Sarcoma Heterogeneity
© CD Steele1; S Behjati2; F Amary3; R Tirabosco4; P Van Loo4; AM Flanagan1; N Pillay1
1UCL Cancer Institute, London, UK; 2Wellcome Trust Sanger Institute, Hinxton, UK; 3Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; 4Francis Crick Institute, London, UK

14.45–15.00
[PL4] Potential Place of Risk-Reducing Salpingectomy in BRCA1/2 Carriers: Prevalence of Malignancies and/or In-Situ Lesions at Risk Reducing Salpingo-Oophorectomy Over a 16 Year Period
F Blok; © S Dasgupta; WNM Dinjens; HJ van Beekhuizen;
© PC Ewing-Graham
Erasmus MC, Rotterdam, NL

15.00–15.30
REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]
PLENARY ORAL PRESENTATIONS (continued)

15.30–15.45 [PL5] Frequent Homologous Recombination Deficiency in High-Grade Endometrial Carcinomas
Presenter: MM de Jonge
Institutes: LUMC, Leiden, NL; Gustave Roussy Cancer Center, Villejuif, France

15.45–16.00 [PL6] Upregulation of Aldo-Keto-Reductase 1C1 and 1C3 (AKR1C1, AKR1C3) is Associated with Poor Prognosis in Oropharyngeal Squamous Cell Carcinomas (OPSCC) Independent of Human Papillomavirus (HPV) Status
Presenter: EJM Speel
Institutes: MUMC+, Maastricht, NL; University of Cologne, Cologne, Germany; British Columbia Cancer Research Center, Vancouver, Canada; University of Giessen, Giessen, Germany

16.00–16.15 [PL7] Predicting the Response to Pre-Operative Short Course Radiotherapy in Rectal Cancer: a Potential Role for Raman Spectroscopy?
Presenter: CJ Kirkby
Institutes: Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; Molecular and Nanoscale Physics Group, University of Leeds, Leeds, UK

PRESENTATIONS AND AWARDS

16.20–16.35 PALGA Award: Best Scientific Paper
Presenter: Prof I Nagtegaal
Institute: Radboud University, Nijmegen, NL

16.35–16.50 Pathological Society: Most Impactful Trainee Award
Presenter: Prof MJ Arends
Institute: Research Sub-Committee, Pathological Society, London; University of Edinburgh, Edinburgh, UK

Digital Pathology: The Evidence Base, Training and Validation
Presenter: Dr B Williams
Institute: Leeds Teaching Hospitals NHS Trust and The University of Leeds, Leeds, UK

THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELAND DONIACH LECTURE
Chair: Prof P Quirke, President, Pathological Society; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

[547] Discovery Pathology and New Approaches to Treatment
Presenter: Prof JE Martin
Institute: Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, UK

CONFERENCE DINNER
Outward buses will depart at 18.45.
Return shuttle buses will be available from 23.00
ACEM (Association of Clinical Electron Microscopists)

**COMPANION MEETING**
Chair: Mr G Anderson, Great Ormond Street Hospital for Children, London, UK
Mr B Wagner, Royal Hallamshire Hospital, Sheffield, UK

**08.40–17.15 COMPANION MEETING Madrid**

**08.40–09.10**
*Adult-onset Still’s Disease: A Presentation of Cases from the West London Renal and Transplant Centre*
Dr L Moran
Charing Cross Hospital, London, UK

**09.10–09.40**
*Understanding IgA Disease*
Dr P Prasad
St James’s University Hospital, Leeds, UK

**09.40–10.30**
REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
OFFICIAL POSTER ROUNDS [Lobby] — See page 47 for details

**10.30–11.00**
*Cornea Case Presentation*
Dr L Angus
Southampton General Hospital, Southampton, UK

**11.00–11.30**
*EM EQA Feedback Session*
Mrs T de Haro
Leicester Royal Infirmary, Leicester, UK

**11.30–11.45**
**GROUP PHOTOGRAPH and SIGNING-IN**

**11.45–12.00**
*Oral Presentation*
**Ultrapath / SUP Meeting Announcement Presentation Amsterdam June 2020***
Dr NN van der Wel
Academic Medical Centre, University of Amsterdam, Amsterdam, NL

**12.00–13.00**
**LUNCH / TRADE EXHIBITION [Trajectum]**
**POSTER VIEWING [Lobby]**

**13.00–14.00**
**ACEM ANNUAL GENERAL MEETING**
Chair: Mr A Page, Medical School, Southampton General Hospital, University of Southampton, Southampton, UK

**14.00–14.30**
*Cilia: New Aspects on their Physiological and Pathophysiological Role*
Dr F Barsch
Department of Pathology, University of Regensburg, Regensburg, Germany

**14.30–15.00**
*Volume EM and Correlative Imaging of Cells and Tissues*
Dr L Collinson
The Francis Crick Institute, London, UK

**15.00–15.30**
REFRESHMENT BREAK / TRADE EXHIBITION [Trajectum]
POSTER VIEWING [Lobby]

**15.30–16.00**
*Beauty and Benefit of Cyro-EM for Understanding Cause and Mechanisms in Disease*
Prof P Peters
University of Maastricht, Maastricht, NL

**16.00–16.30**
*Why EM is Still Useful in the Modern Era of Molecular Genetics*
Dr F van Dijk
Northwick Park and St Mark’s Hospital, London, UK

**16.30–17.00**
*How Much Ultrastructure Do Pathologists Need to Know?*
Dr R Theias Manso
Hospital Fernando Fonseca, Amadora, Lisbon, Portugal

**17.00–17.15**
**DISCUSSION SESSION**
DETAILED PROGRAMME  Friday 22 June 2018

08.00
REGISTRATION and COFFEE

09.00 – 12.25
Auditorium 2

THE TEFAF ONCOLOGY CHAIR SUMMIT
The Future of Cancer Management
Chair: Prof Dr F Ramaekers, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, NL

09.00–09.10 Welcome
Prof Dr F Ramaekers
GROW-School for Oncology and Developmental Biology, MUMC+, Maastricht, NL

Epidemiology and Prevention

09.10–09.40 The Global Cancer Burden: Necessity is the Mother of Prevention
Prof Dr C Wild
International Agency for Research on Cancer, Lyon, France

09.40–10.25 The Prospects of Cancer Prevention
Prof Dr H zur Hausen
Krebshauseninstitut DKFZ, Heidelberg, Germany

10.25–10.55 Refreshment Break [Trajectum]

OncoGenesis and Cancer Biology

10.55–11.25 One Gene, 65 000 papers: So How Does p53 Work?
Prof Sir D Lane

11.25–11.55 DNA Damage at the Core of Cancer and Aging
Prof Dr J Hoeijmakers
Erasmus University MC, Rotterdam, NL

11.55–12.25 Possible Uses of Pluripotent Stem Cells in Disease Modelling and Therapy
Prof Dr C Verfaillie
Interdepartmental Stem Cell Institute Leuven, Catholic University Leuven, Leuven, Belgium

12.25 – 13.35
Trajectum

LUNCH

12.25 – 13.35
MECC Cafe

LUNCH FOR PHD STUDENTS — MEET THE EXPERTS
(Places are limited – separate registration required)

12.35–13.20 Auditorium 2

Industry Sponsored Lunchtime Symposium 4
See page 59 for details

13.35 – 16.45
Auditorium 2
THE TEFAF ONCOLOGY CHAIR SUMMIT — CONTINUED

Cancer Diagnostics

13.35–14.00 Taking the Epigenome to the Cancer Patient
Prof Dr J Herman
University of Pittsburgh Cancer Institute, The Hillman Cancer Center, Pittsburgh, USA

14.00–14.25 Doubling Survival in Bowel Cancer
Prof P Quirke
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK


Cancer Treatment

14.55–15.20 Radiomics
Prof Dr R Gillies
H. Lee Moffitt Cancer Center and Research Institute, Phoenix, USA

15.20–15.45 Restoring Immunosurveillance by Dendritic Cell Vaccines in Cancer Patients
Prof Dr J de Vries
Department of Tumor Immunology and Medical Oncology, Radboud UMC, Nijmegen, NL

15.45–16.45 Plenary Discussion

End of Conference
### Lunchtime Symposium 1
**Thermo Fisher Scientific**
*A look back at four years of using NGS as the default option for somatic variant analysis in common solid tumours. What have we learned?*
Speaker: Dr P Bennett, Principal Clinical Scientist, Sarah Cannon Molecular Diagnostics, London
*Separate lunch will be provided*

### Lunchtime Symposium 2
**Agena Bioscience**
*Liquid Biopsy: A New Concept in Cancer Diagnostics*
Speaker: Prof K Pantel, Institute for Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

### Lunchtime Symposium 3
**Definiens AG**
*Standardised Immunoprofiling of Cancer Tissue for Better Patient Care*
Speaker: Prof Dr R Huss, Chief Medical Officer, Definiens AG, Munich, Germany

### Lunchtime Symposium 4
**Bristol-Myers Squibb BV**
*Immune Checkpoint Inhibitors and Emerging Biomarkers for Thoracic Malignancies*

- **12.35–12.40** Welcome and Opening
  - Prof Dr A-M Dingemans, Maastricht University Medical Centre, Maastricht, NL

- **12.40–12.55** Predictive Profiling of Non-Small Cell Lung Cancer: What to Test and When to Do It
  - Prof J Gosney, Royal Liverpool University Hospital and University of Liverpool, Liverpool, UK

- **12.55–13.10** The Role of Molecular Biomarkers Within the Evolving Treatment Landscape for Advanced NSCLC
  - Prof Dr A-M Dingemans, Maastricht University Medical Centre, Maastricht, NL

- **13.10–13.20** Q&A and Closing Remarks
  - Prof Dr A-M Dingemans, Maastricht University Medical Centre, Maastricht, NL
  - Prof J Gosney, Royal Liverpool University Hospital and University of Liverpool, Liverpool, UK
The British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland wish to acknowledge the support of the following companies:

**AGENA BIOSCIENCE**
We Empower Precision Medicine. Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine. Our highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY® System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, and clinical research. We are a leader dedicated to enabling clinical laboratories worldwide to deliver affordable targeted genomic testing. Our advanced diagnostic platforms support timely, accurate and actionable results, to improve clinical decision making and laboratory economics.

**AGILENT TECHNOLOGIES LDA UK LTD**
Agilent Technologies is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent's expertise and trusted collaboration gives them the highest confidence in our solutions.

**BRISTOL-MYSERS SQUIBB BV**
Bristol-Myers Squibb is a differentiated company, led by a unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

**DEFINIENS AG**
We improve patient lives by unlocking the tissue phenome. Our mission is to accelerate breakthroughs by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, bring multi-omics data into a cancer-relevant context, and facilitate the translation of new insights into novel therapies.

**INVIVOSCRIBE**
Invivoscribe® offers a full range of hematology-oncology molecular testing products and services, such as B- and T-cell clonality assays (IGH, IGK, TRG, TRB), next-generation sequencing (NGS) gene panels and minimal residual disease (MRD) assays with bioinformatics software. All products, including bioinformatics software, are developed under ISO 13485 design control, manufactured in our FDA-registered cGMP facility and used by more than 700 clinical and research partners in over 100 countries. We operate a global network of clinical reference laboratories, offering internationally harmonized tests to support the stratification and enrollment of patients in clinical trials, optimized treatment, and development of companion diagnostics.

**LEICA BIOSYSTEMS**
Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.
TRADE EXHIBITION AND SPONSORS

MAVIG GMBH

MAVIG GmbH, a family owned and operated company founded in 1921 and headquartered in Munich, is a quality and innovation leader in the field of X-ray protection. Lucid, Inc., operating as Caliber Imaging & Diagnostics Inc., based in Rochester, New York (USA), is manufacturer of the VivaScope products. In 2006 MAVIG assumed the confocal laser technology distribution rights for Europe, Russia, the Middle East, and North Africa. Both companies work hand in hand concerning R&D in the field of laser scanning microscopy. The VivaScope product series is successfully used within Europe, as well as internationally.

MENARINI DIAGNOSTICS BENELUX

Menarini is one of Europe’s leading pharmaceutical and healthcare companies, with headquarters in Florence and Rome. Incorporated over 100 years ago, the organization has over forty subsidiaries operating throughout Eastern and Western Europe, with a network of marketing partners covering many other countries throughout the world. The Menarini group consists of pharmaceutical, over-the-counter medicines and diagnostic divisions, as well as several other divisions concerned with bio-medical assessment. The Benelux organisation is now established as one of the fastest growing Diagnostics companies in the Benelux with over 15% annual growth. Our slogan remains: The Human Touch is our Point of Care!

NANOSTRING TECHNOLOGIES

We provide life science tools for translational research and molecular diagnostic products. The nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 1,900 peer-reviewed publications. The nCounter Analysis System offers cost-effective ways to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString technology is also being used in breast cancer diagnostics.

OLYMPUS NEDERLAND B.V.

Olympus Microscopy – imaging systems for every application. Olympus is one of the world’s leading manufacturers of professional opto-digital products for medicine, science and industry. As a result, Olympus provides a comprehensive range of solutions. From microscopes for training and routine tasks to high-end system solutions in the fields of life science, there is a system for every need. Unique are the High Luminosity True LED illumination microscope and camera’s with fast 4K UHD live images possibilities.

TRADE EXHIBITION AND SPONSORS

PHILIPS

Sharing multiplies your knowledge. Philips IntelliSite Pathology Solution is designed to increase efficiency and collaboration in your clinical lab. Next to CE-IVD mark in Europe, Philips IntelliSite Pathology Solution is the first, and only digital pathology solution available for primary diagnosis worldwide. High resolution images, collaboration features and case management support tools can help you make those next steps in workflow improvement and accelerate knowledge sharing amongst your clinical colleagues. See our website: www.philips.com/digitalpathology

QUARTETT GMBH

Quartett was founded 1986 as a family-run company and supplies its customers with biochemicals, reagents, cosmetics and provides a variety of services. Our production site is certified according to EN ISO 9001:2008 and EN ISO 13485:2012+AC:2012 and works in compliance with GMP conformity. Our QMS guarantees products of highest quality. The company specialized its product profile in manufacturing and modification of synthetic peptides with HPLC purity > 95 % including protease inhibitors or peptides for antibody production. Second expertise of quartett is the production of a variety of reagents for histology, cytology and immunohistochemistry including > 8000 antibodies and detection systems.

SECTRA

Digital pathology is part of Sectra’s enterprise imaging solution that also supports radiology, cardiology, mammography, orthopaedics and other medical imaging. Sectra provides a complete solution for primary diagnostics in pathology. It allows seamless sharing of digital slides and patient data in multi-hospital environments, enhancing the workflows around consultations, frozen sections and second opinions. Sectra’s solution enables efficient integrated diagnostic workflows, supporting improved collaboration between radiology and pathology, two key players in efficient cancer care. See our website: www.sectra.com/pathology

TARGOS MOLECULAR PATHOLOGY GMBH

Targos provides premium services for development and application of clinical biomarkers to the pharmaceutical and diagnostic industry. Targos has supported over 300 global clinical trials, leading to the approval of several targeted therapies and IVDs for our customers. Our expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new CDx assays into clinical routine by training courses for the international standardization of biomarkers. Targos is a fully GCPcompliant central laboratory, inspected by the U.S. FDA and accredited by the US-CAP and CLIA.

OLYMPUS NEDERLAND B.V.

Olympus Microscopy – imaging systems for every application. Olympus is one of the world’s leading manufacturers of professional opto-digital products for medicine, science and industry. As a result, Olympus provides a comprehensive range of solutions. From microscopes for training and routine tasks to high-end system solutions in the fields of life science, there is a system for every need. Unique are the High Luminosity True LED illumination microscope and camera’s with fast 4K UHD live images possibilities.
TRADE EXHIBITION AND SPONSORS

**THermo FISHER scIENTIFIC — CLINICAL SEQUENCING DIVISION**

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support clinical oncology research with innovative technologies and service through our technologies on the market, while our cassette and slide printing and block archiving solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.

**THermo FISHER scIENTIFIC — ANATOMICAL PATHOLOGY DIVISION**

Thermo Fisher Scientific is the world leader in serving science. In the Anatomical Pathology Division we understand the value of patient samples and provide histology and cytology instruments and consumables to help give positive patient outcomes. Additionally our cryostat portfolio represents some of the best technology on the market, while our cassette and slide printing and block archiving systems offer complete traceability and security of precious patient specimens. Visit us at Booth 11 to find out how we can help you.

Wiley

Wiley is proud to publish The Journal of Pathology and The Journal of Pathology: Clinical Research, official publications of The Pathological Society, and Histopathology, official journal of the British Division of the International Academy of Pathology. Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.

---

**INDEX TO PRESENTERS**

<table>
<thead>
<tr>
<th>Index to Presenters</th>
<th>Presenter's name followed by abstract number</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
</tr>
<tr>
<td>Abdelsamea, MM</td>
<td>P149, P150</td>
</tr>
<tr>
<td>Acres, MJO</td>
<td>P98</td>
</tr>
<tr>
<td>Adoke, KU</td>
<td>P79, P131</td>
</tr>
<tr>
<td>Ahmed, RN</td>
<td>P82</td>
</tr>
<tr>
<td>Alan, TS</td>
<td>P86</td>
</tr>
<tr>
<td>Alexander, SC</td>
<td>P141</td>
</tr>
<tr>
<td>Al-Kawaz, A</td>
<td>P10</td>
</tr>
<tr>
<td>Alpers, CE</td>
<td>S17, S23</td>
</tr>
<tr>
<td>Al-Ramadhanis, SAA</td>
<td>P84</td>
</tr>
<tr>
<td>A</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Badr, NM</td>
<td>O14, P1</td>
</tr>
<tr>
<td>Begg, CB</td>
<td>S38</td>
</tr>
<tr>
<td>Belete, D</td>
<td>P42</td>
</tr>
<tr>
<td>Bell, C</td>
<td>P105</td>
</tr>
<tr>
<td>Beltran, L</td>
<td>S34</td>
</tr>
<tr>
<td>Bemmer, DM</td>
<td>S42</td>
</tr>
<tr>
<td>Bogie, RMM</td>
<td>P67</td>
</tr>
<tr>
<td>Bouri, S</td>
<td>P145</td>
</tr>
<tr>
<td>Bowee, J</td>
<td>S20</td>
</tr>
<tr>
<td>Brownlee, L</td>
<td>P88</td>
</tr>
<tr>
<td>Büttner, RB</td>
<td>S5</td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>Camerio, F</td>
<td>S18</td>
</tr>
<tr>
<td>Chteinberg, E</td>
<td>O31</td>
</tr>
<tr>
<td>Coleman, Hg</td>
<td>P31, P32, P33</td>
</tr>
<tr>
<td>Conlon, GA</td>
<td>P122</td>
</tr>
<tr>
<td>Cooke, JS</td>
<td>P90</td>
</tr>
<tr>
<td>Craig, SG</td>
<td>P132</td>
</tr>
<tr>
<td>Craze, ML</td>
<td>P9</td>
</tr>
<tr>
<td>Cuppen, E</td>
<td>S9</td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Dalleywater, WJ</td>
<td>P112, P113</td>
</tr>
<tr>
<td>Das Gupta, S</td>
<td>PL4</td>
</tr>
<tr>
<td>de Bruijne, J</td>
<td>S28</td>
</tr>
<tr>
<td>de Jonge, MM</td>
<td>PL5</td>
</tr>
<tr>
<td>Devigere, V</td>
<td>P53</td>
</tr>
<tr>
<td>D’Haene, N</td>
<td>S10</td>
</tr>
<tr>
<td>Dinjens, W</td>
<td>O5, P27</td>
</tr>
<tr>
<td>Dorward, DA</td>
<td>S27</td>
</tr>
<tr>
<td>Dotsenko, O</td>
<td>P22</td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>Elighbashy, M</td>
<td>P3</td>
</tr>
<tr>
<td>Elsheikh, S</td>
<td>O30, O32, P11</td>
</tr>
<tr>
<td>Evers, LAP</td>
<td>O26</td>
</tr>
<tr>
<td>Ewing-Graham, PC</td>
<td>PL4</td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>Fadliseedd, H</td>
<td>P137, P138</td>
</tr>
<tr>
<td>Fernandez-Cuesta, L</td>
<td>S7</td>
</tr>
<tr>
<td>Feyga, AC</td>
<td>S90</td>
</tr>
<tr>
<td>Frijneman, RIA</td>
<td>P29</td>
</tr>
<tr>
<td>Fisher, C</td>
<td>S21</td>
</tr>
<tr>
<td>Fleming, S</td>
<td>S11</td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>Gaitskell, K</td>
<td>P127</td>
</tr>
<tr>
<td>Galoczova, M</td>
<td>P123</td>
</tr>
<tr>
<td>Garry, JMG</td>
<td>P37</td>
</tr>
<tr>
<td>Govinda Rajoo, R</td>
<td>P23</td>
</tr>
<tr>
<td>Green, AR</td>
<td>O13</td>
</tr>
<tr>
<td>Gwitz, P</td>
<td>P104</td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>Haider, A</td>
<td>P83</td>
</tr>
<tr>
<td>Haller, M</td>
<td>P65</td>
</tr>
<tr>
<td>Hanley, CJ</td>
<td>PL2</td>
</tr>
<tr>
<td>Hassall, J</td>
<td>P71</td>
</tr>
<tr>
<td>Hassall, JC</td>
<td>O8</td>
</tr>
<tr>
<td>Hewitt, LC</td>
<td>P62</td>
</tr>
<tr>
<td>Hubbscher, SG</td>
<td>S29</td>
</tr>
<tr>
<td>Hussain, UA</td>
<td>P53</td>
</tr>
<tr>
<td>Hutchins, GGA</td>
<td>O17, P46</td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>Ikeri, NZ</td>
<td>P91</td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>Jacobs, HIL</td>
<td>S34</td>
</tr>
<tr>
<td>Jawad, H</td>
<td>P16, P139</td>
</tr>
<tr>
<td>Johnson, GA</td>
<td>P107</td>
</tr>
<tr>
<td>Juvenal Baena, JBA</td>
<td>P111</td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>Kawachi, H</td>
<td>P78</td>
</tr>
<tr>
<td>Keijbeck, BAA</td>
<td>O29</td>
</tr>
<tr>
<td>Kerr, KM</td>
<td>S6</td>
</tr>
<tr>
<td>Khalid, S</td>
<td>P121</td>
</tr>
<tr>
<td>Kirkby, CJ</td>
<td>PL7, P43</td>
</tr>
<tr>
<td>Klof, M</td>
<td>P63</td>
</tr>
<tr>
<td>Koenmans, WJ</td>
<td>P66</td>
</tr>
<tr>
<td>Komor, MA</td>
<td>P28</td>
</tr>
<tr>
<td>Konings, GFJ</td>
<td>O25</td>
</tr>
<tr>
<td>Kubat, B</td>
<td>S35</td>
</tr>
<tr>
<td>Kuehl, TJ</td>
<td>P135</td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>Lai, JTT</td>
<td>P52, P77</td>
</tr>
<tr>
<td>Lai, LM</td>
<td>P68</td>
</tr>
<tr>
<td>Langer, R</td>
<td>S19</td>
</tr>
<tr>
<td>Latifi, D</td>
<td>P99</td>
</tr>
<tr>
<td>Latten, BGH</td>
<td>P108</td>
</tr>
<tr>
<td>Lazarow Pacheco, D</td>
<td>O1</td>
</tr>
<tr>
<td>Lebrun, L</td>
<td>P57</td>
</tr>
<tr>
<td>Lee, SH</td>
<td>P80</td>
</tr>
<tr>
<td>Leeman, A</td>
<td>P76</td>
</tr>
<tr>
<td>Lewis, JJ</td>
<td>P94</td>
</tr>
<tr>
<td>Lightenberg, MJK</td>
<td>S16</td>
</tr>
<tr>
<td>Lillis, O</td>
<td>P109</td>
</tr>
<tr>
<td>Lommen, K</td>
<td>P125</td>
</tr>
<tr>
<td>Loughrey, MB</td>
<td>S36</td>
</tr>
<tr>
<td>Lugli, A</td>
<td>S14</td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Mackintosh, LC</td>
<td>P48, P49</td>
</tr>
<tr>
<td>Macklin, P</td>
<td>O35</td>
</tr>
<tr>
<td>Mailinger, FD</td>
<td>P20</td>
</tr>
<tr>
<td>Marks, KM</td>
<td>O15</td>
</tr>
<tr>
<td>Martin, JE</td>
<td>S47</td>
</tr>
<tr>
<td>Masood, MS</td>
<td>P81, P95</td>
</tr>
<tr>
<td>McCaffrey, J</td>
<td>P100</td>
</tr>
<tr>
<td>McLaren, A</td>
<td>P35</td>
</tr>
<tr>
<td>McMillan, RF</td>
<td>P118</td>
</tr>
<tr>
<td>Mehdi, MZM</td>
<td>P75</td>
</tr>
<tr>
<td>Meijer, T</td>
<td>P13</td>
</tr>
<tr>
<td>Melotte, V</td>
<td>O11</td>
</tr>
<tr>
<td>Presenter's name followed by abstract number</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Merard, R</td>
<td>P2</td>
</tr>
<tr>
<td>Miligy, IM</td>
<td>P8</td>
</tr>
<tr>
<td>Mistry, SKM</td>
<td>P24, P142</td>
</tr>
<tr>
<td>Mooi, WJ</td>
<td>S24, S39</td>
</tr>
<tr>
<td>Mukherjee, A</td>
<td>P73, P74</td>
</tr>
<tr>
<td>Mullan, G</td>
<td>P54</td>
</tr>
<tr>
<td>Murphy, JK</td>
<td>P136</td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Naiki-Ito, A</td>
<td>O21</td>
</tr>
<tr>
<td>Oliver, TRW</td>
<td>P47</td>
</tr>
<tr>
<td>Orsi, NM</td>
<td>P147</td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Padayachy, S</td>
<td>P92, P93</td>
</tr>
<tr>
<td>Perez-Casanova, L</td>
<td>O19</td>
</tr>
<tr>
<td>Pillay, NP</td>
<td>P103</td>
</tr>
<tr>
<td>Pinto, D</td>
<td>S46</td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>Quiohilag, K</td>
<td>P20</td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>Raine, JI</td>
<td>P51</td>
</tr>
<tr>
<td>Rajguru, A</td>
<td>P34</td>
</tr>
<tr>
<td>Raposo, TP</td>
<td>P116, P148, P151</td>
</tr>
<tr>
<td>Rashid, F</td>
<td>P7</td>
</tr>
<tr>
<td>Rathbone, VM</td>
<td>P97</td>
</tr>
<tr>
<td>Richards, AE</td>
<td>P6</td>
</tr>
<tr>
<td>Richman, SD</td>
<td>P45</td>
</tr>
<tr>
<td>Roemen, G</td>
<td>O3</td>
</tr>
<tr>
<td>Rogers, E</td>
<td>P96</td>
</tr>
<tr>
<td>Roufosse, C</td>
<td>O28</td>
</tr>
<tr>
<td>Roufosse, CA</td>
<td>O27, P101</td>
</tr>
<tr>
<td>Ruisch, J</td>
<td>P63</td>
</tr>
<tr>
<td>Ruminaite, A</td>
<td>P140</td>
</tr>
<tr>
<td>Ryan, CB</td>
<td>P18</td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Santos Moreira Pedrosa, RM</td>
<td>P60</td>
</tr>
<tr>
<td>Satomi, K</td>
<td>O20</td>
</tr>
<tr>
<td>Schuuring, E</td>
<td>S8</td>
</tr>
<tr>
<td>Sciot, RME</td>
<td>S22</td>
</tr>
<tr>
<td>Selo-Ojeme, U</td>
<td>P30</td>
</tr>
<tr>
<td>S</td>
<td>CONTINUED</td>
</tr>
<tr>
<td>Seth, S</td>
<td>P19</td>
</tr>
<tr>
<td>Severens-Rijvers, CAH</td>
<td>P130</td>
</tr>
<tr>
<td>Shaaban, AM</td>
<td>PL1</td>
</tr>
<tr>
<td>Shah, PJ</td>
<td>P44</td>
</tr>
<tr>
<td>Shepherd, NA</td>
<td>S15</td>
</tr>
<tr>
<td>Sherring, K</td>
<td>P85</td>
</tr>
<tr>
<td>Simons, CCJ</td>
<td>P64</td>
</tr>
<tr>
<td>Smits, KM</td>
<td>P124</td>
</tr>
<tr>
<td>Spaans, LN</td>
<td>P117</td>
</tr>
<tr>
<td>Speel, EJM</td>
<td>PL6, P134</td>
</tr>
<tr>
<td>Speirs, V</td>
<td>S12</td>
</tr>
<tr>
<td>Sredic-Rhodes, A</td>
<td>O10</td>
</tr>
<tr>
<td>Steele, CD</td>
<td>PL3</td>
</tr>
<tr>
<td>Stephens, ML</td>
<td>P152</td>
</tr>
<tr>
<td>Stouthard, JML</td>
<td>S1</td>
</tr>
<tr>
<td>Susanti, S</td>
<td>P69, P70, P72</td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Tarvala, U</td>
<td>P25</td>
</tr>
<tr>
<td>Thomas, JS</td>
<td>S3</td>
</tr>
<tr>
<td>Thunnissen, E</td>
<td>S4, O6</td>
</tr>
<tr>
<td>Titiloye, NA</td>
<td>P50</td>
</tr>
<tr>
<td>Tobin-O’Brien, CPF</td>
<td>P17</td>
</tr>
<tr>
<td>Toss, M</td>
<td>P89</td>
</tr>
<tr>
<td>Toss, MS</td>
<td>P12</td>
</tr>
<tr>
<td>Tupper, PM</td>
<td>P128</td>
</tr>
<tr>
<td>Turnquist, CT</td>
<td>P58</td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>Urbanowicz, M</td>
<td>S45, S46</td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>van Bekkum, S</td>
<td>P4</td>
</tr>
<tr>
<td>Van Bockstal, MR</td>
<td>O12</td>
</tr>
<tr>
<td>van de Pol, JAA</td>
<td>O33</td>
</tr>
<tr>
<td>van den Brandt, PA</td>
<td>S37</td>
</tr>
<tr>
<td>van den Oord, JJ</td>
<td>S40</td>
</tr>
<tr>
<td>van der Leden, A</td>
<td>P87</td>
</tr>
<tr>
<td>Van der Valk, P</td>
<td>O7</td>
</tr>
<tr>
<td>van der Wel, MJ</td>
<td>O16</td>
</tr>
<tr>
<td>van Dooijeweert, C</td>
<td>O2, P14</td>
</tr>
<tr>
<td>van Krieken, JHJ</td>
<td>S33</td>
</tr>
<tr>
<td>Van Laere, SJ</td>
<td>S13</td>
</tr>
<tr>
<td>van Leenders, A</td>
<td>S44</td>
</tr>
<tr>
<td>Varma, M</td>
<td>S43</td>
</tr>
<tr>
<td>Vaysse, PM</td>
<td>O22</td>
</tr>
<tr>
<td>Verheij, J</td>
<td>S30</td>
</tr>
<tr>
<td>Versteeg, R</td>
<td>S26</td>
</tr>
<tr>
<td>Villamor, E</td>
<td>S25</td>
</tr>
<tr>
<td>Vroobel, KM</td>
<td>S31</td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>Waise, S</td>
<td>O4</td>
</tr>
<tr>
<td>West, NP</td>
<td>P39</td>
</tr>
<tr>
<td>Westenend, PJ</td>
<td>P15</td>
</tr>
<tr>
<td>Westwood, AC</td>
<td>O9, P38, P40, P41</td>
</tr>
<tr>
<td>Wiesner, T</td>
<td>S41</td>
</tr>
<tr>
<td>Wilgenhof, K</td>
<td>P129</td>
</tr>
<tr>
<td>Wilkinson, N</td>
<td>S32</td>
</tr>
<tr>
<td>Williams, J</td>
<td>P5</td>
</tr>
<tr>
<td>Wood, JC</td>
<td>P146</td>
</tr>
<tr>
<td>Woods, GB</td>
<td>P133</td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Yates, JR</td>
<td>P55, P56</td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Zhang, ZH</td>
<td>P36</td>
</tr>
<tr>
<td>Zwart, W</td>
<td>S2</td>
</tr>
</tbody>
</table>